Perform G6PD deficiency testing prior to initiating treatment.
Obtain hematocrit and hemoglobin prior to initating treatment and at day 3 and 8 in patients with mild to moderate G6PD deficiency, unknown status, or where testing is unavailable.
Obtain blood cell counts and hemoglobin determinations in G6PD normal patients.
Closely observe patients with a previous idiosyncratic reaction to primaquine, history of hemolytic anemia, or nicotinamide adenine dinucleotide methemoglobin reductase deficiency.
Monitor EGC in patients with cardiac disease or with concomitant use of QT interval prolonging drugs.